District Court Decision Teaches Caution When Construing Claims to Encompass After-Arising Technology
Novartis is currently involved in a multi-district patent litigation campaign to block generic entrants for its blockbuster heart medication. On July 7, the district court invalidated the patent for lack of written description despite rejecting an enablement defense based upon the same evidence.
Source: ipwatchdog.com
